Oncology

Your Article Summary

See Latest Articles

Concurrent validity of the PSYCH-6, a very short scale for detecting anxiety and depression, among oncology outpatients
Australian and New Zealand Journal of Psychiatry, 06/22/09

Clover K et al. - The PSYCH-6 scale of the SPHERE-12 at a cut-off point of 3 is an equivalent instrument to the HADS-T for detecting cases and excluding non-cases of anxiety and depression and is suitable for deployment in oncology populations.

• Cross-sectional survey of 340 oncology outpatients attending a regional hospital in Newcastle, Australia.
• The performance of the PSYCH-6 against the Hospital Anxiety and Depression Scale (HADS) was evaluated using correlation, Cohen's kappa, positive agreement and negative agreement.

• The PSYCH-6 subscale of the SPHERE-12, at a cut-off point of 3, had substantial agreement with the total score of the HADS (HADS-T; κ = 0.73, p < 0.001).
• Negative agreement (0.92) was marginally higher than positive agreement (0.80).

Today in Side Effects...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes
Journal of Clinical Oncology, 11/12/09

Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
Supportive Care in Cancer, 11/06/09

Incidence and Correlates of Radiation Dermatitis in Children and Adolescents Receiving Radiation Therapy for the Treatment of Paediatric Sarcomas
Clinical Oncology, 11/12/09

See All of Side Effects